Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label

Who is this study for? Children, adolescents and adult patients with tuberous sclerosis complex
What treatments are being studied? Sirolimus
Status: Recruiting
Location: See all (8) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric subjects with tuberous sclerosis complex (TSC).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 21
Healthy Volunteers: No
View:

• Generally healthy males or non-pregnant females aged 2 to 21 years, inclusive, at the time of screening.

• Diagnosis of TSC with visible facial angiofibromas of at least grade 3 up to grade 5, inclusive, based on the IGA.

• Subjects with 3 or more isolated, measurable lesions of facial angiofibroma, with color grading score ≥2 for each of the 3 lesions.

• Females of childbearing potential must have a negative urine pregnancy test (or a negative serum pregnancy test if a urine pregnancy test cannot be obtained) (For China, different pregnancy test would be followed) and if sexually active or become sexually active during the study, must agree to use an effective form of birth control for the duration of the study. Females using oral contraceptives must also use a barrier method of contraception during the study. Sexually active male subjects and/or their female partners should also use appropriate contraception.

• Effective contraception is defined as follows:

• Oral/implant/injectable/transdermal/estrogenic vaginal ring contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide.

• Abstinence or partner's vasectomy are acceptable if the female agrees to implement one of the other acceptable methods of birth control if her partner changes.

• The subject and/or their parent or guardian must be willing and able to provide written informed consent/assent.

• Willing and able to comply with all trial requirements.

• Subject or parent/guardian must be able to complete the subject self-assessment survey and subject diary in English or another language into which the documents have been officially translated.

• Subjects should be in good general health based on the subject's medical history, physical exam, and impression of the study doctor.

Locations
United States
Arizona
Translational Genomics Research
Completed
Phoenix
California
Children's Hospital of Los Angeles, Division of Neurology
Recruiting
Los Angeles
Colorado
Children's Clinical Research Organization, Children's Hospital Colorado
Completed
Aurora
Georgia
Children's Healthcare of Atlanta
Completed
Atlanta
Massachusetts
Boston Children's Hospital
Recruiting
Boston
Pennsylvania
Children's Hospital of Philadelphia
Recruiting
Philadelphia
Tennessee
LeBonheur Children's Hospital
Completed
Memphis
Other Locations
China
Children's Hospital of Fudan University
Recruiting
Shanghai
Contact Information
Primary
Rosa West
rosa.west@auctapharma.com
732-652-9225
Backup
Wilson Chang
wilson.chang@auctapharma.com
732-640-6030
Time Frame
Start Date: April 12, 2017
Estimated Completion Date: March 2023
Participants
Target number of participants: 45
Treatments
Active Comparator: Arm 1
Sirolimus 0.2% ointment applied topically hs x 12 weeks
Active Comparator: Arm 2
Sirolimus 0.4% ointment applied topically hs x 12 weeks
Placebo Comparator: Arm 3
Placebo ointment applied topically hs x 12 weeks
Sponsors
Leads: Aucta Pharmaceuticals, Inc

This content was sourced from clinicaltrials.gov

Similar Clinical Trials